

Accelaron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/AF43D1D4964EN.html>

Date: March 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: AF43D1D4964EN

Abstracts

Accelaron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acceleron Pharma Inc (Acceleron) is a clinical stage biopharmaceutical company that discovers, develops and commercializes drugs to treat serious and rare diseases. Reblozyl is the company's only commercial product used for the treatment of transfusion-dependent anemia patients with beta thalassemia and myelodysplastic syndromes (MDS). The company's lead therapeutic candidate, luspatercept-aamt is in trials for the treatment of anemia and associated complications in myelodysplastic syndromes, and myelofibrosis. Its other pipeline products are being evaluated for the treatment of lung disease. The company has operations in the US, Bermuda and Switzerland. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc Key Recent Developments

Feb 25,2021: Acceleron reports fourth quarter and full year 2020 financial results

Feb 17,2021: Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Nov 05,2020: Acceleron announces third quarter 2020 REBLOZYL net sales

Nov 05,2020: Acceleron reports third quarter 2020 operating and financial results

Sep 16,2020: Acceleron appoints Laura J. Hamill to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Accelaron Pharma Inc - Key Facts
Accelaron Pharma Inc - Key Employees
Accelaron Pharma Inc - Key Employee Biographies
Accelaron Pharma Inc - Major Products and Services
Accelaron Pharma Inc - History
Accelaron Pharma Inc - Company Statement
Accelaron Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Accelaron Pharma Inc - Business Description
Accelaron Pharma Inc - Corporate Strategy
Accelaron Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Accelaron Pharma Inc - Strengths
Accelaron Pharma Inc - Weaknesses
Accelaron Pharma Inc - Opportunities
Accelaron Pharma Inc - Threats
Accelaron Pharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Accelaron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD

2021

Accelaron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD

2021

Accelaron Pharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 25, 2021: Accelaron reports fourth quarter and full year 2020 financial results

Feb 17, 2021: Accelaron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Nov 05, 2020: Accelaron announces third quarter 2020 REBLOZYL net sales

Nov 05, 2020: Accelaron reports third quarter 2020 operating and financial results

Sep 16, 2020: Accelaron appoints Laura J. Hamill to its Board of Directors

Aug 06, 2020: Accelaron announces second quarter 2020 REBLOZYL Net Sales

Aug 06, 2020: Accelaron reports second quarter 2020 operating and financial results

Jun 04, 2020: Accelaron appoints Christopher Hite to its board of directors

Jun 04, 2020: Accelaron Pharma: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

May 11, 2020: Accelaron reports first quarter 2020 operating and financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Accelaron Pharma Inc, Key Facts
Accelaron Pharma Inc, Key Employees
Accelaron Pharma Inc, Key Employee Biographies
Accelaron Pharma Inc, Major Products and Services
Accelaron Pharma Inc, History
Accelaron Pharma Inc, Subsidiaries
Accelaron Pharma Inc, Key Competitors
Accelaron Pharma Inc, Ratios based on current share price
Accelaron Pharma Inc, Annual Ratios
Accelaron Pharma Inc, Annual Ratios (Cont...1)
Accelaron Pharma Inc, Interim Ratios
Accelaron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Accelaron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Accelaron Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Accelaron Pharma Inc, Performance Chart (2016 - 2020)

Accelaron Pharma Inc, Ratio Charts

Accelaron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

Accelaron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD
2021

I would like to order

Product name: Acceleron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/AF43D1D4964EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF43D1D4964EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970